XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.98

+3.9%

Dec 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (16232)	8/9/2003 9:17:10 AM
From: Robert K.	Read Replies (1) of 17367

Bluegreen> I found your methotrexate quite interesting so I posted your idea to the Yahoo board. There is a excellent poster there that seems to know a lot about RA. Here is his reply to me. Comments here are welcome and encouraged> >The results of the hu1124 rheumatoid athritis trial were disappointing but not surprising since the antibody was used in combination with methotrexate. While some inhibitors of integrins (such as LFA-1) can show synergy with inhibitors that affect certain cellular pathways, in some instances just the opposite is true. This is especially the case given new insights regarding the unexpected effects of methotrexate on a signaling pathway known as Ras that can profundly affect integrins. Thus, it will require a more simplified clinical study uncomplicated by inhibitors of intersecting pathways to fully understand the utility of hu1124. It is likely that if Genentech/Xoma does not conduct such trials other companies developing antibody and small molecule inhibitors of integrins will do so. There is still a possibility that hu1124 will prove effective in this chronic T cell-mediated disease

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next